Search Results
Your search for ,ASh matches 1521 pages
Showing 1401 - 1450ASH Recognizes Curt Civin, MD, and Craig Kitchens, MD, MACP, for Outstanding Mentorship
The American Society of Hematology (ASH) will honor Curt Civin, MD, and Craig Kitchens, MD, MACP, with 2015 Mentor Awards at the 57th ASH Annual Meeting and Exposition in Orlando, Florida, for their sustained, outstanding commitment to the training and career development of early-career...
2015 Oncology Meetings
DECEMBER Markers in Cancer 2015December 1-2 • Brussels, Belgium For more information: http://markersincancer.org 9th European Colorectal Congress (ECC)December 1-4 • St.Gallen, Switzerland For more information: www.colorectalsurgery.eu Advances in Cancer ImmunotherapyTMDecember 4 • New Orleans,...
ASH Selects Medical Students and Residents for HONORS Award
The American Society of Hematology (ASH) has announced the names of 18 medical students and 10 residents selected to receive a 2015 ASH HONORS Award. The ASH HONORS Award aims to support hematology research projects for North American medical students and residents who are interested in hematology...
Barbara Furie, PhD, and Bruce Furie, MD, to Present 2015 ASH E. Donnall Thomas Lecture
The American Society of Hematology (ASH) will honor Barbara Furie, PhD, of Harvard Medical School, and Bruce Furie, MD, of Beth Israel Deaconess Medical Center and Harvard Medical School, with the 2015 E. Donnall Thomas Lecture for their groundbreaking research in hemostasis and thrombosis over the ...
ASH Honors Nancy Speck, PhD, and Karl Welte, MD, With 2015 Henry M. Stratton Medal
The American Society of Hematology (ASH) will recognize Nancy Speck, PhD, of the University of Pennsylvania Perelman School of Medicine, and Karl Welte, MD, of Hannover Medical School, with the 2015 Henry M. Stratton Medal for their seminal contributions in the areas of basic and...
Alfred Goldberg, PhD, and Paul Richardson, MD, to Present 2015 ASH Ernest Beutler Lecture
The American Society of Hematology (ASH) will honor Alfred Goldberg, PhD, of Harvard Medical School, and Paul Richardson, MD, of Dana-Farber Cancer Institute, with the 2015 Ernest Beutler Lecture and Prize for their significant research advances in the area of proteasome inhibitors and their...
The State of Progress in Hematologic Malignancies
The number of targeted therapies approved by the U.S. Food and Drug Administration (FDA) in the treatment of a variety of cancers, especially hematologic malignancies, continues to rise. In 2014 alone, 4 of the 10 new agents directed at discrete molecular targets approved by the FDA were for blood...
ASH Announces Stephen S. Chung, MD, as Inaugural Jake Wetchler Foundation ASH Scholar for Pediatric Innovation Recipient
The American Society of Hematology (ASH) recently announced that Stephen S. Chung, MD, will receive the inaugural Jake Wetchler Foundation ASH Scholar Award for Pediatric Innovation for his research on the mechanisms of bone marrow failure syndromes. This work could ultimately lead to an improved...
Changing the Outlook for Chronic Lymphocytic Leukemia
Small-molecule inhibitors, especially ibrutinib (Imbruvica) and idelalisib (Zydelig), have greatly changed the outlook for patients with chronic lymphocytic leukemia. William G. Wierda, MD, PhD, Professor and Center Medical Director in the Department of Leukemia at The University of Texas MD...
Chronic Myelogenous Leukemia: What Drug for Which Patient?
Treatment of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors is “the golden child success story of targeted treatment,” Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, Seattle, Washington, told attendees at the National...
2015-2016 Oncology Meetings
DECEMBER American Society for Cell Biology Annual MeetingDecember 12-16 • San Diego, California For more information: http://ascb.org/2015meeting/ ESMO Asia 2015 CongressDecember 18-21 • Singapore For more information: www.esmo.org/Conferences/ESMO-Asia-2015-Congress JANUARY 2016 4th AACR-IASLC...
2016 Oncology Meetings
JANUARY 2016 4th AACR-IASLC International Joint Conference: Lung Cancer Translational ScienceJanuary 4-7 • San Diego, CaliforniaFor more information: http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=74#.VbbijqTbJjo Genitourinary Cancers SymposiumJanuary 7-9 • San Francisco,...
ASH Announces 2016 Scholar Award Recipients
The American Society of Hematology (ASH) has announced the recipients of its 2016 Scholar Awards. One of ASH’s most prestigious award programs, the ASH Scholar Award program financially supports fellows and junior faculty dedicated to careers in hematology research as they transition from training...
ASH Awards Inaugural Giuseppe Bigi Memorial Award in Hematopoiesis and Stem Cells to Marilena Ciciarello, PhD
The American Society of Hematology (ASH) named Marilena Ciciarello, PhD, of the University of Bologna, the inaugural recipient of the ASH Giuseppe Bigi Memorial Award for Achievement in Hematopoiesis and Stem Cells for her research on the role of stem cells in leukemia initiation and progression....
ASH Honors Baseball Hall of Famer With Outstanding Service Award
The American Society of Hematology (ASH) recognized Rod Carew, Baseball Hall of Famer and Advocate for the National Marrow Donor Program (NMDP)/Be the Match, at the 57th ASH Annual Meeting and Exposition in Orlando, Florida, for his outstanding support of biomedical research and the practice of...
Acute Myeloid Leukemia in the Elderly: Trial Data Stir Hope for the Transplant Option
Older patients with acute myeloid leukemia (AML) have high relapse rates after induction chemotherapy, low survival rates, and fewer treatment options compared with younger patients. One of the options for both younger and older patients is hematopoietic cell transplantation, but relatively few...
Selected Abstracts From 2015 ASH Annual Meeting
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting therapeutics in acute leukemias and myelodysplastic syndromes. For full details of these study abstracts, visit...
Charles S. Abrams, MD, Named President of ASH
Charles S. Abrams, MD, the Francis C. Wood Professor of Medicine, Pathology, and Laboratory Medicine at the Perelman School of Medicine and Abramson Cancer Center of the University of Pennsylvania and Director of the Blood Center for Patient Care & Discovery at Penn and The Children’s Hospital ...
Pediatric Regimen Achieves Higher-Than-Expected Survival in Young Adults With Acute Lymphoblastic Leukemia
Adolescents and younger adults with acute lymphoblastic leukemia (ALL) had superior outcomes on a “pediatric” regimen compared with adult treatment protocols. A multicenter phase II study included patients aged 18–50, extending the upper limit of “younger,” since most other trials of this approach...
Promising Upfront Combination in Older Patients With Acute Lymphoblastic Leukemia
Frontline treatment with the antibody-drug conjugate inotuzumab ozogamicin plus deintensified chemotherapy is a promising option for older patients with Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). Phase II results suggest that this combination has the ability to improve...
ASH Announces Top Trainee Abstracts of 2015 Annual Meeting
The American Society of Hematology (ASH) recognized investigators with the highest-scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow at the 57th ASH Annual Meeting and Exhibition, December 5–8 in Orlando,...
Midostaurin: A New Standard of Care in Acute Myeloid Leukemia?
Upfront treatment with midostaurin added to standard chemotherapy improved survival compared with placebo plus chemotherapy in high-risk patients with acute myeloid leukemia (AML) characterized by FLT3 mutations. No new drugs have been approved for AML since 1990, and midostaurin is the first...
Ibrutinib Bests Standard of Care for Elderly Patients With CLL
First-line treatment with the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) significantly reduced the risk of dying or disease progression compared with chlorambucil (Leukeran) in older treatment-naive patients with chronic lymphocytic leukemia (CLL) in the RESONATE-2 trial. At the time...
Impressive Results With Daratumumab Plus Lenalidomide/Dexamethasone in Multiple Myeloma
The anti-CD38 monoclonal antibody daratumumab (Darzalex) took center stage among multiple myeloma studies presented at the 57th American Society of Hematology Annual Meeting and Exposition. In relapsed/refractory patients, daratumumab plus lenalidomide (Revlimid)/dexamethasone yielded an 81%...
Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD, on Venetoclax for NHL
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and John F. Gerecitano, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss a phase I study of venetoclax monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma, including updated safety and efficacy data...
David Henry, MD, on Anticoagulants: Expert Perspective
David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.
Sagar Lonial, MD, and Alessandra Tedeschi, MD, on CLL/SLL: Results From the RESONATE-2 Trial
Sagar Lonial, MD, of the Emory University School of Medicine, and Alessandra Tedeschi, MD, of the Azienda Ospedaliera Niguarda Cà Granda, discuss this international study of ibrutinib vs chlorambucil in patients 65 years and older with treatment-naive chronic lymphocytic leukemia or small...
Sagar Lonial, MD, on Multiple Myeloma: How I Treat Newly Diagnosed Patients
Sagar Lonial, MD, of Emory University School of Medicine, summarizes his educational session on this vital topic.
Sagar Lonial, MD, and Torben Plesner, MD, on Multiple Myeloma: Updated Results of the Phase I/II GEN503 Study
Sagar Lonial, MD, of Emory University School of Medicine, and Torben Plesner, MD, of Vejle Hospital, discuss the latest findings on the use of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (Abstract 507).
Mikkael A. Sekeres, MD, on MDS and CMML Study Results: SWOG S1117
Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses an additional analysis of a phase II study of azacitidine combined with lenalidomide or with vorinostat vs azacitidine monotherapy in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia (Abstract 908).
Kieron Dunleavy, MD, on Burkitt Lymphoma: Preliminary Report of the DA-EPOCH-R Trial
Kieron Dunleavy, MD, of the National Cancer Institute, discusses a multi-center trial that set out to validate the effectiveness of DA-EPOCH-R-based therapy and whether a risk-adapted approach using the regimen is beneficial for patients with Burkitt lymphoma (Abstract 342).
James N. Kochenderfer, MD, on Multiple Myeloma: Results of a First-in-Humans Clinical Trial
James N. Kochenderfer, MD, of the National Cancer Institute, reports on remissions of multiple myeloma during a trial of T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor (Abstract 99).
James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara
James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and as the basis for consolidation in nonfavorable AML (Abstracts 217 and 218).
Nathan Hale Fowler, MD, on Follicular Lymphoma: Ibrutinib Plus Rituximab Study Results
Nathan Hale Fowler, MD, of MD Anderson Cancer Center, discusses a multicenter trial in which ibrutinib plus rituximab was administered to treatment-naive patients with follicular lymphoma (Abstract 470).
Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine
Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating agent in 103 treatment-naïve AML patients who were not candidates for intensive chemotherapy (Abstract 458).
S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs
S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes a special FDA-sponsored session on the three myeloma drugs that were approved this November––daratumumab, ixazomib, and elotozumab––and their current and future roles in treating the disease.
Alok A. Khorana, MD, on Preventing Venous Thromboembolism
Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).
Margaret O'Donnell, MD, on Novel Approaches to Treatment for Older AML Patients
Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).
Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin
Craig H. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I study of an anti-CD19 monoclonal antibody used in relapsed/refactory B-lineage non-Hodgkin lymphoma (Abstract 182).
Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus
Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).
Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease
Stephen J. Schuster, MD, of the University of Pennsylvania, discusses the findings of a study of chimeric antigen receptor modified T cells directed against CD19 in patients with relapsed or refractory disease (Abstract 183).
Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemotherapy, have excellent outcomes without the need for consolidative radiotherapy, regardless of disease ...
John Leonard, MD, on DLBCL: Results From the Pyramid Trial
John Leonard, MD, of Weill Cornell Medical College, discusses this phase II study of R-CHOP with or without bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma (Abstract 811).
S. Vincent Rajkumar, MD, on Advances in Myeloma
S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes his education session on the evolving diagnostic criteria for myeloma, which focused on smoldering disease and when it becomes an “open flame.”
David Henry, MD, on Multiple Myeloma: Expert Perspective
David Henry, MD, of Pennsylvania Hospital, discusses the exciting developments in multiple myeloma treatment, including the three new drugs approved for the disease in November 2015.
Andrew J. Davies, MRCP, PhD, on DLBCL: The Remodl-B Clinical Trial Results
Andrew J. Davies, MRCP, PhD, of the Cancer Research UK Centre, University of Southampton, discusses a study of targeted treatment for diffuse large B-cell lymphoma based on real-time gene-expression profiling (Abstract 812).
Andrew D. Zelenetz, MD, PhD, and Stephan Stilgenbauer, MD, PhD on CLL and Venetoclax: Clinical Trial Results
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Stephan Stilgenbauer, MD, PhD, of the University of Ulm, discuss this late-breaking abstract on venetoclax monotherapy and deep remissions in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p...
Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and David Straus, MD, of Memorial Sloan Kettering Cancer Center, discuss the initial results of the U.S. Intergroup Trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for nonbulky stage I and II...
Julie Vose, MD, MBA, and Rafat Abonour, MD, on Multiple Myeloma: The Path to a Cure
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Rafat Abonour, MD, of Indiana University Simon Cancer Center, discuss the session that he chaired on the question of whether researchers can design therapy that addresses the heterogeneity of the disease and eradicate most if...
David A. Williams, MD, on the Goals and Highlights of ASH 2015
Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.
